1. Search Result
Search Result
Results for "

macroautophagy

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101106
    AR7
    10+ Cited Publications

    RAR/RXR Neurological Disease Cancer
    AR7 is an atypical RARA/RARα (retinoic acid receptor, alpha) antagonist. AR7 specifically activates chaperone-mediated-autophagy (CMA) activity without affecting macroautophagy .
    AR7
  • HY-112698
    CA-5f
    4 Publications Verification

    p62 Atg8/LC3 Autophagy Apoptosis Cancer
    CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity .
    CA-5f
  • HY-161739

    p62 Cancer
    YOK-1304 is a ligand of p62-ZZ domain. YOK-1304 can activate p62-dependent selective macroautophagy. YOK-1304 can be used for AUTOTAC design .
    YOK-1304
  • HY-W489121

    p62 Autophagy Cancer
    YTK-105 is a p62/ZZ binding domain ligand and Autophagy enhancer. YTK-105 activates p62-dependent selective macroautophagy. YTK-105 serves as an autophagy-targeting ligand (ATL) for synthesizing AUTOTAC degraders .
    YTK-105
  • HY-161742

    AUTOTACs MetAP Autophagy p62 Cancer
    Fumagilin-105 is an autophagy-targeting chimera (AUTOTAC) that degrades MetAP2 via p62-mediated macroautophagy in a ubiquitination-independent manner. Fumagilin-105 can inhibit the migration of tumor cells and induce programmed cell death. Fumagilin-105 has anti-tumor activity. (p62-ZZ ligand (HY-W489121); target-binding ligand (HY-B0751); linker (HY-W245803)) .
    Fumagilin-105
  • HY-161738

    p62 Cancer
    YOK-2204 is a ligand of p62-ZZ domain. YOK-2204 can activate p62-dependent selective macroautophagy. YOK-2204 can be used for AUTOTAC design .
    YOK-2204
  • HY-161737

    p62 Cancer
    YT-8-8 is a ligand of p62-ZZ domain. YT-8-8 can activate p62-dependent selective macroautophagy. YT-8-8 can be used for AUTOTAC design .
    YT-8-8
  • HY-125465

    Autophagy Cancer
    SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) .
    SLLN-15
  • HY-101106R

    RAR/RXR Reference Standards Neurological Disease Cancer
    AR7 (Standard) is the analytical standard of AR7 (HY-101106). This product is intended for research and analytical applications. AR7 is an atypical RARA/RARα (retinoic acid receptor, alpha) antagonist. AR7 specifically activates chaperone-mediated-autophagy (CMA) activity without affecting macroautophagy .
    AR7 (Standard)
  • HY-180188

    Autophagy Cardiovascular Disease Cancer
    F1-ispinesib is a heterobifunctional F1-autophagy degrader, composed of an RNA-binding fragment (F1) and the LC3B ligand Ispinesib (HY-50759). F1-ispinesib induces degradation of COL15A1 mRNA via an LC3B-dependent macroautophagy mechanism. F1-ispinesib inhibits cell proliferation and enhances migration of human aortic smooth muscle cells .
    F1-ispinesib
  • HY-182269

    Cathepsin Apoptosis PARP Caspase Cancer
    Cathepsin-IN-5 is a cathepsin inhibitor with IC50 values of 6.2 μM and 81 nM for cathepsin L and cathepsin S. Cathepsin-IN-5 inhibits cancer cells proliferation, induces apoptosis, reduces growth of hepatocellular tumors in mouse models, and modulates expression of genes linked to cell death, cell proliferation, and cellular processes. Cathepsin-IN-5 can be used for the research of hepatocellular carcinoma .
    Cathepsin-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: